

Santen Announces Change of Representative Director of the Board (change in CEO)

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka, President and CEO: Takeshi Ito) today announced that its Board of Directors has approved the following management changes as described below.

1. Reasons for change

Shigeo Taniuchi, Santen's Representative Director of the Board, President and CEO, offered to resign from his position for personal reasons. The Board of Directors thereby appointed Representative Director of the Board, Executive Vice President, Takeshi Ito, as President and CEO on September 12, 2022.

2. Change

(Newly appointed)

Name: Takeshi Ito

New Position: Representative Director of the Board, President and CEO

Former Position: Representative Director of the Board, Executive Vice President,
Head of Japan Business, Head of Japan Sales and Marketing Division

(Resignation)

Name: Shigeo Taniuchi

Former Position: Representative Director of the Board, President and CEO

*Shigeo Taniuchi has also resigned from his position as Director of the Board

3. Profile of the newly appointed Representative Director of the Board, President and CEO

Name: Takeshi Ito

Number of shares held: 37,370 (As of September 12, 2022)

Date of Birth: July 16, 1959

Profile

Apr 1982	Joined the Company
Dec 2002	Head of R&D Integration Department, R&D Division
Apr 2007	Head of Surgical Division
Apr 2012	Corporate Officer, Head of Prescription Pharmaceuticals Sales Department, Sales and Marketing Division, Prescription Pharmaceuticals
Apr 2014	Senior Corporate Officer, Head of Japan Sales and Marketing Division, Prescription Pharmaceuticals
Apr 2016	Executive Corporate Officer, Japan Business, Head of Japan Sales and Marketing Division, Prescription Pharmaceuticals
Jun 2017	Director of the Board, Executive Corporate Officer, Japan Business, Head of Japan Sales and Marketing Division, Prescription Pharmaceuticals
Apr 2019	Director of the Board, Executive Corporate Officer, Head of Japan Business,

	Head of Japan Sales and Marketing Division
Apr 2022	Representative Director of the Board, Executive Vice President, Head of Japan Business, Head of Japan Sales and Marketing Division

Reason for appointment of new President and CEO

Takeshi Ito, the new Representative Director of the Board, President and CEO, has been involved in management of the entire company including overseas business as a Representative Director of the Board and Executive Vice President. In addition, he has been overseeing Japan Business and Japan Sales and Marketing Division.

Since 2012, he had led Japan Business, which is a core area of business for Santen as Head of Prescription Pharmaceuticals Sales Department, and since 2016, he has been overseeing Japan Business and contributed to increasing sales from 90 billion yen to 160 billion yen.

Also, he has experience in pipeline development and sales & marketing system development, which are the important value chains in pharmaceutical companies.

In order to promote the transformation that enables sustainable growth and further value creation as well as enhancing our corporate value, capabilities of seeing the big picture of the healthcare market and identifying key opportunities and seizing them by thoroughly implementing action plans are essential. We believe Mr. Ito is the right person for the position of Representative Director of the Board, President and CEO, as he possesses these capabilities and has a proven track record.

4. Effective date

September 12, 2022

5. Others

From September 12, 2022 Santen has 2 Representative Directors of the Board, Akira Kurokawa, Representative Director of the Board, Chairman, and Takeshi Ito, Representative Director of the Board, President and CEO.

Post this Director of the Board resignation, the condition pertaining to the number of directors as stipulated by law and the articles of incorporation has been met.

Contact:

Guillaume Sakuma
Global Head of IR, IR Group
E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en/>).